Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXL01 maintenance in Crohn's Disease
NCT05542355Phase 1Terminated
- Sponsor
- Exeliom Biosciences
- Start
- Mar 2023
- Primary completion
- Oct 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of exl01 in Crohn's disease (3 arms), sponsored by Exeliom Biosciences. Primary endpoint: Systemic and intestinal safety and tolerability up to 43 weeks. Started Mar 2023; status: terminated.
02
Drugs
exl01
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05542355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05542355.